Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734627 | SCV000862783 | uncertain significance | not provided | 2018-08-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002440583 | SCV002748220 | uncertain significance | Cardiovascular phenotype | 2022-04-19 | criteria provided, single submitter | clinical testing | The p.V927I variant (also known as c.2779G>A), located in coding exon 23 of the JAG1 gene, results from a G to A substitution at nucleotide position 2779. The valine at codon 927 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV002536524 | SCV003256906 | benign | Alagille syndrome due to a JAG1 point mutation | 2023-09-27 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005029400 | SCV005656283 | uncertain significance | Alagille syndrome due to a JAG1 point mutation; Tetralogy of Fallot; Deafness, congenital heart defects, and posterior embryotoxon; Charcot-Marie-Tooth disease, axonal, Type 2HH | 2024-03-28 | criteria provided, single submitter | clinical testing |